Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.